News Release

Influenza vaccination programmes for children in USA and Canada based on little evidence

NB. Please note that if you are outside North America, the embargo lifts 0001 hours UK time Friday, February 25, 2005 (London time).

Peer-Reviewed Publication

The Lancet_DELETED

Children in the USA and Canada are being vaccinated against influenza without adequate proof that it will work, concludes a study published in this week's issue of THE LANCET.

Most immunisation campaigns target people aged 65 years or older. The USA and Canada have recently started vaccinating children, including those aged 6 to 24 months, in the hope of reducing disease spread, admissions and visits to hospitals, deaths of elderly relatives, complications (such as ear infections and pneumonia), absences from school, and parental loss of workdays and over-prescribing of antibiotics. However, there is no evidence that vaccinating children can achieve these goals.

Tom Jefferson (Cochrane Vaccines Field, Italy) and colleagues identified and assessed 25 comparative studies that evaluated the efficacy (reduction in laboratory confirmed case) and effectiveness (reduction in symptomatic cases) on influenza vaccines in healthy children aged 16 years or younger.

Vaccines of live viruses with weakened infectivity had 79% efficacy and 38% effectiveness in children older than two years compared with placebo or no immunisation. Inactivated vaccines had a lower efficacy (65%) than live weakened vaccines, and in children aged two years or younger they had similar effects to placebo. Effectiveness of inactivated vaccines was about 28% in children older than two years. Vaccines were effective in reducing long school absences but had little effect on other outcomes such as hospital stays and lower respiratory tract disease, when compared with placebo or no intervention. However, the authors note that these conclusions are based on a small number of studies.

Dr Jefferson concludes: "We have identified a large dataset showing reasonable quality evidence of efficacy of influenza vaccines in children age 2 years or older, especially for two-dose live attenuated vaccines. However, we noted a striking difference between efficacy and effectiveness of vaccines because of the large proportion of influenza-like illness caused by agents other than influenza viruses. This is an important point in the decision to immunise whole populations. Immunisation of very young children is not lent support by our findings. Although a growing body of evidence shows effect of influenza on admissions and deaths of children, we recorded no convincing evidence that vaccines can reduce mortality, hospital admissions, serious complications and community transmission of influenza."

###

Contact: Dr Tom Jefferson, Cochrane Vaccines Field, Via Adige 28a 00061 Anguillara Sabazia, Roma, Italy.
T) 39-06-999-00-989 or 39-3-292-025-051.

On Feb 26 T) 01505 706665/ 07789 484067 toj1@aol.com
Contact co-author: Dr Vittorio Demicheli T) 39-349-464-5360


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.